| Vol. 9.42 – 4 November, 2020 |
| |
|
|
| Researchers showed that the Special AT‐rich Binding Protein‐2 (SATB2), one of the crucial nuclear matrix‐associated proteins, recruited histone acetyltransferase CBP to promote the FOXM1‐mediated cell proliferation and tumor growth of glioblastoma. [EMBO Molecular Medicine] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| High-throughput RNA-sequencing analysis from pancreatic tissues of KCM animals revealed a significant decrease in cancer stem cell markers Aldh1a1, Klf4, EpCAM, and CD133. [Cancer Research] |
|
|
|
| The transcriptomes of primary tumors and metastases in mice harboring estrogen receptor+ breast cancer patient-derived xenografts were analyzed following single-cell RNAseq. In vitro assays were employed to delineate mechanisms of endocrine resistance and stemness. [British Journal of Cancer] |
|
|
|
| The authors revealed that the lncRNA LHFPL3-AS1-long, generated from the polypyrimidine tract binding protein 1-mediated splicing of the LHFPL3-AS1 precursor, upregulated B-cell lymphoma-2 (BCL2) protein to contribute to tumorigenesis of melanoma stem cells. [Cell Death & Disease] |
|
|
|
| Investigators proposed to standardize a liquid biopsy platform to identify hotspot mutations in BRAF, NRAS and TERT in plasma samples from advanced melanoma patients and investigated whether it was associated to clinical outcome. [Scientific Reports] |
|
|
|
| Scientists showed that ionizing radiation specifically enhanced the motility and invasiveness of human glioma stem cells through the stabilization and nuclear accumulation of the hypoxia-inducible factor 1α (HIF1α), which in turn transcriptionally activated the Junction-mediating and regulatory protein. [Scientific Reports] |
|
|
|
| The authors investigated the cellular energetics of two triple‐negative breast cancer stem cells treated with two pharmacological doses of vitamin C that generated reactive oxygen species. [Journal of Cellular Biochemistry] |
|
|
|
| Treatment with Tideglusib alone and in combination with radiation significantly decreased the colony formation of U-251 MG cells and the sphere formation of both cell lines, by targeting and reducing their glioblastoma cancer stem-like cell population. [Pharmacological Reports] |
|
|
|
| CD133‑positive osteosarcoma CSCs were first isolated and cultured by magnetic cell sorting and serum‑free medium suspension cell sphere culture, respectively. [International Journal of Molecular Medicine] |
| |
|
|
|
| Two models have been proposed to explain the cell of origin of breast cancer and involve either the reprogramming of differentiated mammary cells or the dysregulation of mammary stem cells or progenitors. Both hypotheses are not exclusive and imply the accumulation of independent mutational events. [Neoplasia] |
|
|
|
|
| Astex Pharmaceuticals, Inc. announced it has entered into a Cooperative Research and Development Agreement with the US National Cancer Institute, part of National Institutes of Health. The agreement calls for a range of new clinical and translational studies of oral decitabine and cedazuridine tablets as an anticancer agent to be conducted in collaboration with Astex. [Astex Pharmaceuticals, Inc.] |
|
|
|
| AIVITA Biomedical, Inc. announced that treatment has been completed for all 57 patients in the Phase II clinical trial of AV-GBM-1 in patients with glioblastoma. The company was able to manufacture final product at a notable 94% success rate, showing strong commercial and clinical viability. [AIVITA Biomedical, Inc.] |
|
|
|
|
| March 17 – March 19, 2021 Virtual |
|
|
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
| IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
| Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| The University of Chicago – Chicago, Illinois, United States |
|
|
|
|